Omacetaxine: Clinical Trials

5 trials of Omacetaxine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 12Active not recruiting 1, Withdrawn 1

Follow Omacetaxine: new trials by email Literature Review of Omacetaxine trials Research Report on Omacetaxine

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
Omacetaxine, Azacitidine - High Grade Myelodysplastic Syndromes
Phase 1 / Phase 2Active not recruitingUniversity of Colorado, Denver292018-09-172026-11-06
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
Omacetaxine, Azacitidine, G-CSF - Myelodysplastic Syndromes
Phase 1 / Phase 2WithdrawnUniversity of Florida2016-08-012017-05-03
Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
Omacetaxine - Leukemia
Phase 2CompletedM.D. Anderson Cancer Center482015-05-182021-06-09
Omacetaxine for Consolidation and Maintenance
Omacetaxine - Acute Myelogenous Leukemia (AML)
Phase 2TerminatedEmory University72013-05-012019-09-24
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Omacetaxine, Cytarabine - Leukemia
Phase 2CompletedM.D. Anderson Cancer Center362011-07-012018-05-30

Conditions studied

Leukemia (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Myelodysplastic Syndromes (2)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Emory University (1)  ·  University of Colorado, Denver (1)  ·  University of Florida (1)

Countries

United States (5)

Top investigators

Daniel Pollyea, MD (1)  ·  Elias Jabbour, MD (1)  ·  Hagop Kantarjian, MD (1)  ·  Martha L. Arellano, MD (1)  ·  Maxim N. Norkin, MD, PhD (1)

Results publications

PMID 41140451